Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • AllergoOncology (1)
  • Eosinophilic esophagitis (9)
  • Mastocytosis and mast cells (11)
Poster available until
  • Until platform closure (1)
Poster categories
  • Thematic Poster Session (25)
keywords
Session Reference
  • L-TPS01 (11)
  • L-TPS02 (15)
  • L-TPS03 (14)
  • L-TPS04 (12)
  • L-TPS05 (13)
  • L-TPS06 (8)
  • L-TPS07 (11)
  • L-TPS08 (7)
  • L-TPS09 (13)
  • L-TPS10 (13)
  • L-TPS11 (12)
  • L-TPS12 (14)
  • L-TPS13 (13)
  • L-TPS14 (11)
  • L-TPS15 (7)
  • L-TPS16 (14)
  • L-TPS17 (13)
  • L-TPS18 (10)
  • L-TPS19 (10)
  • L-TPS20 (12)
  • L-TPS21 (12)
  • TPS01 (12)
  • TPS02 (8)
  • TPS03 (14)
  • TPS04 (9)
  • TPS05 (15)
  • TPS06 (11)
  • TPS07 (13)
  • TPS08 (9)
  • TPS09 (9)
  • TPS10 (16)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (15)
  • TPS16 (15)
  • TPS17 (12)
  • TPS18 (10)
  • TPS19 (7)
  • TPS20 (11)
  • TPS21 (5)
  • TPS22 (3)
  • TPS23 (4)
  • TPS25 (12)
  • TPS26 (14)
  • TPS27 (12)
  • TPS28 (16)
  • TPS29 (16)
  • TPS30 (14)
  • TPS31 (15)
  • TPS32 (16)
  • TPS33 (14)
  • TPS34 (17)
  • TPS35 (15)
  • TPS36 (12)
  • TPS37 (15)
  • TPS38 (13)
  • TPS39 (14)
  • TPS40 (13)
  • TPS41 (9)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (8)
  • TPS47 (7)
  • x TPS48 (5)
  • TPS49 (5)
  • TPS51 (12)
  • TPS52 (14)
  • TPS53 (8)
  • TPS54 (15)
  • TPS55 (13)
  • TPS56 (16)
  • TPS57 (12)
  • TPS58 (12)
  • TPS59 (13)
  • TPS60 (14)
  • TPS61 (11)
  • TPS62 (9)
  • TPS63 (10)
  • TPS64 (11)
  • TPS65 (8)
  • TPS66 (9)
  • TPS67 (9)
  • TPS68 (19)
  • TPS69 (8)
  • x TPS70 (9)
  • x TPS71 (11)
  • TPS72 (6)
  • TPS73 (5)
  • TPS75 (4)
25 results
Thumbnail

D2.430 - Two cases of acquired angioedema: one with splenic lymphoma and the other with Waldenström’s macroglobulinemia

Thumbnail

D2.431 - Association of serum IgE levels and atopic status with cancer in the general population

Thumbnail

D2.433 - AllergoOncology: Immunocompetent 3D and Skin Organoid Models of Melanoma to Investigate Tumour-Immune Interactions and Immunotherapies

Thumbnail

D2.434 - AllergoOncology: Novel crusade for Basophil Activation Test

Thumbnail

D2.432 - Blood morphology in health & cancer: comparative, preliminary study on 783 patients

Thumbnail

D3.399 - Age-Dependent Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic esophagitis

Thumbnail

D3.402 - Potential role of Advanced Glycation End-products in Pediatric Eosinophilic Esophagitis

Thumbnail

D3.403 - Dupilumab improves multiple histopathologic features of eosinophilic esophagitis over 52 weeks: Post hoc analysis of the phase 3 LIBERTY EoE TREET study

Thumbnail

D3.404 - Disease induction in a mouse model of eosinophilic esophagitis is lymphocyte dependent

Thumbnail

D3.405 - Clinical Characteristics and Treatment Response of Eosinophilic Esophagitis in Pediatric Patients: A Descriptive Study from a High-Complexity Colombian Institution

Thumbnail

D3.406 - Experience of dupilumab in difficult-to-treat eosinophilic esophagitis - A Case Series of 6 Portuguese Patients

Thumbnail

D3.407 - Clinic-pathological characteristics and comorbidities in adult patients with eosinophilic esophagitis in Greece

Thumbnail

D3.409 - Eosinophilic esophagitis and hen's egg tolerance: two cases highlighting remission with strongly heated but not less heated hen's egg despite topical steroid treatment

Thumbnail

D3.410 - A concurrence of eosinophilic esophagitis and eosinophilic gastritis in a patient with hypereosinophillia

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM